Literature DB >> 28940169

The Use of d2 and Benton Tests for Assessment of Attention Deficits and Visual Memory in Teenagers with Phenylketonuria.

Bozena Didycz1, Magdalena Nitecka2, Miroslaw Bik-Multanowski3.   

Abstract

Hyperphenylalaninemia-related, subtle deficits of attention and of working memory are often reported in adolescents with phenylketonuria. Focused neuropsychological tests can be used to detect such deficits and to confirm the presence of poor metabolic control in the periods between routine blood phenylalanine tests, which are rarely performed in many patients from this age group due to their low treatment adherence.We assessed the practical value of the d2 test of attention and of the Benton visual retention test for identification of teenagers, who have a high risk of brain dysfunction due to hyperphenylalaninemia. We analyzed the correlation between neuropsychological test scores achieved by 30 patients and their blood phenylalanine profiles since the neonatal period.We observed strong correlation between the Concentration Performance scores on the d2 test and the quality of metabolic control within last month prior to the follow-up visit in the outpatient clinic (r = -0.72; p = 0.0003). The mean z-score was significantly higher in patients with good metabolic control than in those with poorly controlled hyperphenylalaninemia (0.44 vs. -1.12; p = 0.00002). On contrary, the results of the Benton visual retention test did not correlate significantly with the individual blood phenylalanine profiles.We believe that neuropsychological assessment should be used in adolescents with phenylketonuria on a regular basis in order to increase the self-awareness in these patients and, consequently, to increase their treatment adherence and safety. The d2 test can be effectively used for detection of attention deficits and seems to be a valuable supplementary procedure for routine follow-up.

Entities:  

Keywords:  Brain dysfunction in PKU; Metabolic control; Neuropsychological follow-up; Treatment adherence

Year:  2017        PMID: 28940169      PMCID: PMC6122018          DOI: 10.1007/8904_2017_60

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  9 in total

Review 1.  Key European guidelines for the diagnosis and management of patients with phenylketonuria.

Authors:  Francjan J van Spronsen; Annemiek Mj van Wegberg; Kirsten Ahring; Amaya Bélanger-Quintana; Nenad Blau; Annet M Bosch; Alberto Burlina; Jaime Campistol; Francois Feillet; Maria Giżewska; Stephan C Huijbregts; Shauna Kearney; Vincenzo Leuzzi; Francois Maillot; Ania C Muntau; Fritz K Trefz; Margreet van Rijn; John H Walter; Anita MacDonald
Journal:  Lancet Diabetes Endocrinol       Date:  2017-01-10       Impact factor: 32.069

2.  Routine use of CANTAB system for detection of neuropsychological deficits in patients with PKU.

Authors:  Miroslaw Bik-Multanowski; Jacek J Pietrzyk; Renata Mozrzymas
Journal:  Mol Genet Metab       Date:  2010-10-28       Impact factor: 4.797

Review 3.  Phenylketonuria.

Authors:  Nenad Blau; Francjan J van Spronsen; Harvey L Levy
Journal:  Lancet       Date:  2010-10-23       Impact factor: 79.321

Review 4.  Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence.

Authors:  G M Enns; R Koch; V Brumm; E Blakely; R Suter; E Jurecki
Journal:  Mol Genet Metab       Date:  2010-06-22       Impact factor: 4.797

5.  Challenges and pitfalls in the management of phenylketonuria.

Authors:  François Feillet; Francjan J van Spronsen; Anita MacDonald; Friedrich K Trefz; Mübeccel Demirkol; Marcello Giovannini; Amaya Bélanger-Quintana; Nenad Blau
Journal:  Pediatrics       Date:  2010-07-12       Impact factor: 7.124

Review 6.  Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses.

Authors:  M J de Groot; M Hoeksma; N Blau; D J Reijngoud; F J van Spronsen
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

7.  Effects of concurrent phenylalanine levels on sustained attention and calculation speed in patients treated early for phenylketonuria.

Authors:  E Schmidt; P Burgard; A Rupp
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

8.  Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis.

Authors:  Susan E Waisbren; Kay Noel; Kyle Fahrbach; Catherine Cella; Diana Frame; Alex Dorenbaum; Harvey Levy
Journal:  Mol Genet Metab       Date:  2007-06-25       Impact factor: 4.797

9.  How practical are recommendations for dietary control in phenylketonuria?

Authors:  J H Walter; F J White; S K Hall; A MacDonald; G Rylance; A Boneh; D E Francis; G J Shortland; M Schmidt; A Vail
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

  9 in total
  2 in total

1.  Blood phenylalanine instability strongly correlates with anxiety in phenylketonuria.

Authors:  Bozena Didycz; Miroslaw Bik-Multanowski
Journal:  Mol Genet Metab Rep       Date:  2017-12-27

2.  The use of personal protection equipment does not negatively affect paramedics' attention and dexterity: a prospective triple-cross over randomized controlled non-inferiority trial.

Authors:  Calvin Lukas Kienbacher; Jürgen Grafeneder; Katharina Tscherny; Mario Krammel; Verena Fuhrmann; Maximilian Niederer; Sabine Neudorfsky; Klaus Herbich; Wolfgang Schreiber; Harald Herkner; Dominik Roth
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2022-01-10       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.